Canada Markets closed

NervGen Pharma Corp. (NGEN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
2.6200-0.0400 (-1.50%)
At close: 03:59PM EST

NervGen Pharma Corp.

Three Bentall Centre
Suite 1703 595 Burrard Street
Vancouver, BC V7X 1J1
604 488 5421

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. William Joseph Radvak BAScExec. Chairman130.5kN/A1963
Mr. Paul Anthony Brennan B.Sc., M.Sc.Pres, CEO & Director394.1kN/AN/A
Mr. William J. Adams C.A., CPA, CA, CPACFO & Corp. Sec.265.8kN/A1962
Dr. Ernest Shing-Yan WongConsultant & Advisor442.01kN/A1968
Mr. Robert G. Pilz B.Com., C.P.A., BComm, CMAConsultant37.5k34.6k1966
Mr. Brian McAlisterCo-Founder & AdvisorN/AN/AN/A
Dr. Daniel Mikol M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


NervGen Pharma Corp., a clinical stage biotech company, discovers and develops treatments for patients suffering from medical conditions related to nerve damage. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Corporate Governance

NervGen Pharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.